AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2004 JAN 1 - (NewsRx.com & NewsRx.net) -- Platelet-derived endothelial cell growth factor marks ovarian cancer behavior.
According to researchers in Japan, "we investigated the clinical significance of platelet-derived endothelial cell growth factor (PD-ECGF) as measured by enzyme-linked immunosorbent assay in primary epithelial ovarian cancers (EOC), finding amounts to be significantly greater in cancers than in normal ovarian tissue (p
"Further, PD-ECGF was significantly lower in mucinous than in serous adenocarcinomas (p <2 vs.>2 cm), or presence of demonstrable malignant cells in peritoneal fluid," reported Y. Watanabe and colleagues, Kinki University, School of Medicine.
"In stage III disease, PD-ECGF exhibited significant correlation with recurrence (p
Watanabe and colleagues published their study in Cancer Letters (Platelet-derived endothelial cell growth factor predicts of progression and recurrence in primary epithelial ovarian cancer. Cancer Lett, 2003;200(2):173-176).
For more information, contact Y. Watanabe, Kinki University, School of Medicine, Department ...
Source: HighBeam Research, Platelet-derived endothelial cell growth factor marks ovarian cancer...